MAPT and Alzheimer disease: The first-in-human study using 18F-PI-2620 showed an accumulation of the radiotracer in regions of the brain known to have tau depositions, as well as increased uptakes of 18F-PI-2620 in patients with AD compared to healthy controls [77].